Avid Bioservices and Eliem Therapeutics, both NASDAQ-listed medical companies, are compared based on institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends, and risk. Avid Bioservices has a higher volatility but stronger consensus rating and possible upside compared to Eliem Therapeutics. With 97.2% institutional ownership, Avid Bioservices is favored by hedge funds and large money managers. Avid Bioservices operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries, offering various services including clinical and commercial manufacturing of biologics. Eliem Therapeutics focuses on developing therapies for neuronal excitability disorders in psychiatry, epilepsy, chronic pain, and other nervous system disorders.
Read more from cbinsights.com
